Search research articles
Contact Us
Filters
Showing results (11-20 of 70) with videos related to
Page
of 7
Sort By:
Clinical Pharmacology and Therapeutics
|
July 2, 2016
Novel Disease-Drug Database Demonstrating Applicability for Pharmacogenomic-Based Prescribing
M Whirl-Carrillo, K Sangkuhl, L Gong, et al.
Biochimica Et Biophysica Acta
|
April 19, 1990
The structure-activity relationship of the papain hydrolysis of N-benzoylglycine esters
C M Compadre, C Hansch, T E Klein, et al.
Chemico-Biological Interactions
|
January 1, 1988
QSAR analysis of the subtilisin hydrolysis of X-phenyl hippurates. II. A study of subtilisin BPN'
A Carotti, C Raguseo, T E Klein, et al.
Clinical Pharmacology and Therapeutics
|
September 2, 2011
Pharmacogenetics: call to action
M V Relling, H J Guchelaar, D M Roden, et al.
Biopolymers
|
February 13, 2001
Computed free energy differences between point mutations in a collagen-like peptide
S D Mooney, C C Huang, P A Kollman, et al.
Clinical Pharmacology and Therapeutics
|
February 12, 2015
Enabling the curation of your pharmacogenetic study
E m McDonagh, M Whirl-Carrillo, R B Altman, et al.
Biochemistry
|
July 28, 1987
Photoaffinity analogues of methotrexate as folate antagonist binding probes. 1. Photoaffinity labeling of murine L1210 dihydrofolate reductase and amino acid sequence of the binding region
E M Price, P L Smith, T E Klein, et al.
Journal of Medicinal Chemistry
|
October 23, 1998
Quantitative structure-activity relationships of 2, 4-diamino-5-(2-X-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase
C D Selassie, W X Gan, L S Kallander, et al.
Protein Science : a Publication of the Protein Society
|
May 25, 1999
Macromolecular docking of a three-body system: the recognition of human growth hormone by its receptor
D K Hendrix, T E Klein, I D Kuntz, et al.
Clinical Pharmacology and Therapeutics
|
April 30, 2017
Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole
T J Walsh, B Moriyama, S R Penzak, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 70) with videos related to
Sort By:
Page
of 7
Clinical Pharmacology and Therapeutics
|
July 2, 2016
Novel Disease-Drug Database Demonstrating Applicability for Pharmacogenomic-Based Prescribing
M Whirl-Carrillo, K Sangkuhl, L Gong, et al.
Biochimica Et Biophysica Acta
|
April 19, 1990
The structure-activity relationship of the papain hydrolysis of N-benzoylglycine esters
C M Compadre, C Hansch, T E Klein, et al.
Chemico-Biological Interactions
|
January 1, 1988
QSAR analysis of the subtilisin hydrolysis of X-phenyl hippurates. II. A study of subtilisin BPN'
A Carotti, C Raguseo, T E Klein, et al.
Clinical Pharmacology and Therapeutics
|
September 2, 2011
Pharmacogenetics: call to action
M V Relling, H J Guchelaar, D M Roden, et al.
Biopolymers
|
February 13, 2001
Computed free energy differences between point mutations in a collagen-like peptide
S D Mooney, C C Huang, P A Kollman, et al.
Clinical Pharmacology and Therapeutics
|
February 12, 2015
Enabling the curation of your pharmacogenetic study
E m McDonagh, M Whirl-Carrillo, R B Altman, et al.
Biochemistry
|
July 28, 1987
Photoaffinity analogues of methotrexate as folate antagonist binding probes. 1. Photoaffinity labeling of murine L1210 dihydrofolate reductase and amino acid sequence of the binding region
E M Price, P L Smith, T E Klein, et al.
Journal of Medicinal Chemistry
|
October 23, 1998
Quantitative structure-activity relationships of 2, 4-diamino-5-(2-X-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase
C D Selassie, W X Gan, L S Kallander, et al.
Protein Science : a Publication of the Protein Society
|
May 25, 1999
Macromolecular docking of a three-body system: the recognition of human growth hormone by its receptor
D K Hendrix, T E Klein, I D Kuntz, et al.
Clinical Pharmacology and Therapeutics
|
April 30, 2017
Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole
T J Walsh, B Moriyama, S R Penzak, et al.
Page
of 7